TherapeuticsMD Inc. buy tamam
Summary
This prediction ended on 05.11.21 with a price of €32.50. The BUY prediction by tamam for TherapeuticsMD Inc. performed very badly with a performance of -84.30%. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| TherapeuticsMD Inc. | -7.937% | -7.937% | -46.626% | -96.449% |
| iShares Core DAX® | -1.670% | -1.001% | 10.864% | 12.563% |
| iShares Nasdaq 100 | -4.184% | -1.145% | 37.458% | 41.078% |
| iShares Nikkei 225® | -4.967% | -5.783% | 18.828% | 0.655% |
| iShares S&P 500 | -2.834% | -0.572% | 25.875% | 39.960% |
Comments by tamam for this prediction
In the thread Therapeuticsmd Inc. diskutieren
TherapeuticsMD, Inc., an innovative women’s healthcare company!
Cantor Fitzgerald rates TherapeuticsMD as overweight, saying the launches of Imvexxy, Bijuva, and Annovera drugs for women are underappreciated.
Analysts led by Louise Chen says "peak sales could exceed modest expectations. Price target of $27.
Analyst ratings: 7 buys, 0 holds, 0 underperform/sells.
On Mon December 5, 2016 TherapeuticsMD announced positive top-line results from its pivotal phase 3 Replenish Trial of TX-001HR.
The FDA has approved TherapeuticsMD's BIJUVA (estradiol and progesterone) capsules, 1 mg/100 mg, for the treatment of moderate to severe vasomotor symptoms due to menopause
in women with a uterus.
It is the first and only FDA-approved bio-identical hormone therapy combination of estradiol and progesterone.
Der Produktkandidat TX-001HR ist eine neuartige Kombination von Estradiol und Progesteron (
identisch in der chemischen Struktur) zur Behandlung von vasomotorischen Symptomen (VMS) im Zusammenhang mit der Menopause, um vor allem tägliche Hitzewallungen und Nachtschweiß oft in der Menopause zu reduzieren.
Es wird geschätzt, dass mehr als 90% der Frauen VMS erleben. Die meisten bewerten die Schwere der Hitzewallungen als mäßig bis schwer.
In the thread Trading Therapeuticsmd Inc.
Stopped prediction by tamam for TherapeuticsMD Inc.
TherapeuticsMD Inc.
18.03.17
27.09.17
27.09.17
